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Abstract
Objective.—To arrive at consensus for candidate outcomes for disease activity assessment in 
large-vessel vasculitis (LVV) in clinical trials.
Methods.—A Delphi survey including 99 items was circulated among international experts for 3 
rounds.
Results.—Fifty-seven items were accepted for both giant cell arteritis and Takayasu arteritis. 
Sixty-seven percent of experts voted to have a common approach for both diseases with additional 
disease-specific items such as weight loss, scalp tenderness/necrosis, morning stiffness, dizziness, 
visual symptoms, and imaging.
Conclusion.—This study highlights similarities and differences in experts’ perspectives for 
assessing clinical activity in LVV and may guide a consensus-driven core set of validated 
outcomes.
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Large-vessel vasculitis (LVV) is a rare disease mainly affecting the aorta and its primary 
branches1,2,3. LVV usually has a relapsing-remitting course leading to prolonged periods of 
seemingly “clinically inactive” disease during which arterial damage can still progress. In 
clinical practice, physicians managing cases of LVV combine subjective clinical data with 
fairly unreliable laboratory markers and imaging. A comprehensive review of the literature 
demonstrated that not only are there no widely accepted or standardized outcome tools in 
LVV, but also there are not even broadly accepted definitions of important outcomes such as 
“disease activity” or “response to therapy4.”
The OMERACT Vasculitis Working Group is advancing a research agenda that includes 
parallel projects to understand the perspectives and insight into outcomes of importance in 
LVV of (1) experienced physicians and investigators, and (2) patients4. An international 
Delphi exercise was conducted to identify items considered important when determining 
active disease status in LVV in clinical trials. Specifically, the Delphi aimed to determine (1) 
experts’ consensus opinions on the disease domains/subdomains of importance to study in 
LVV, and (2) a preliminary set of outcomes and outcome instruments to use to identify key 
data on the domains. The ultimate goal of our project was to establish a core set of domains 
and validated outcome measures for use in clinical research in LVV. It has been argued that 
the 2 major types of LVV, giant cell arteritis (GCA) and Takayasu arteritis (TA), may not be 
distinct entities, but are part of a single disease spectrum5,6. Thus, the Delphi process also 
aimed to determine whether clinicians feel one common outcome measure could be used to 
assess disease activity in both GCA and TA.
MATERIALS AND METHODS
The Delphi survey was sent by e-mail to 317 experts in LVV who are involved in clinical 
research in vasculitis and/or attended academic vasculitis meetings (Appendix 1). Particular 
attention was paid to ensure inclusion of different geographic areas and medical specialties. 
Information was collected regarding participants’ practice setting, specialty, country, and 
level of experience, measured by the number of cases they followed in their career with 
GCA and TA.
The following question was asked for multiple proposed items in the survey: “Should the 
following item be used to assess disease activity in TA/GCA in clinical trials?” The 
participants voted for GCA and TA separately. The first round included 99 items on a 5-
point scale (strongly disagree, disagree, neutral, agree, and strongly agree), in addition to the 
option of saying “don’t know.” Items were chosen with the aim of being initially 
comprehensive, including items from published disease activity assessment tools 
[Birmingham Vasculitis Activity Score (BVAS), Indian Takayasu Arteritis Score (ITAS), 
Disease Extension Index in TA] or used by prior clinical investigations4,7,8,9 (Supplementary 
Table 1, available with the online version of this article). Participants were given the option 
to give feedback and suggest other items in the first round. The 104 comments received from 
the participants were discussed by all investigators (SZA, HD, PAM) and it was decided that 
7 items would be added in the subsequent rounds. Items accepted or rejected by > 70% of 
voters were not advanced to subsequent rounds. Sixty-two items were voted for GCA and 63 
for TA in the second round and 24 items for GCA and 28 items for TA were voted in Round 
3. The voting results of the participants who had seen > 10 cases (in each subtype of LVV)
in their career were also analyzed and compared to the result of the less experienced
participants.
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RESULTS
The first, second, and third rounds were completed by 148, 111, and 108 participants from 
23 countries, respectively. Experts represented multiple relevant medical specialties 
[rheumatology, (n = 75), internal medicine (n = 5), cardiology (n = 1) vascular surgery (n = 
4), nephrology (n = 8), pediatric rheumatology (n = 6), ophthalmology (n = 5), and 
radiology (n = 4)]. The primary setting of the participants was academic (93%), and 61% 
had been working for more than 10 years.
Ninety-six participants had seen > 10 cases of GCA and 84 participants had seen > 10 cases 
of TA in their life; the results from these more experienced participants were carried through 
to the final round.
Items commonly accepted for both GCA and TA. Fifty-seven items were accepted for both 
GCA and TA. These items covered a wide range of manifestations (Table 1 and Table 2).
Items excluded for both GCA and TA. Many items were excluded for both diseases, 
including anorexia, arthritis, von Willebrand factor antigen, leukocyte count, fibrinogen 
levels, edema, pyoderma gangrenosum, digital ulcers, oral ulcers, gangrene, erythema 
nodosum, cardiomyopathy, bloody diarrhea, seizures, organic brain syndrome, dementia, 
peripheral and cranial neuropathy, psychosis, photophobia, respiratory findings and renal 
findings (other than rise in blood pressure). Among patient-reported outcomes, the 
Nottingham Health Profile, EQ-5D, and the Health Assessment Questionnaire (HAQ) were 
excluded. The physician-based assessments BVAS and ITAS were excluded for both 
diseases. Within imaging findings, only arterial wall enhancement was not accepted for both 
forms of vasculitis.
Items accepted only for GCA or TA. Items differently endorsed for GCA or TA are listed in 
Table 3.
“Can/should we develop 1 common outcome measure for TA and GCA?” Sixty-seven 
percent of experts voted for a common approach for GCA and TA, but also endorsed 
development of additional disease-specific instruments; 11% agreed with aiming to develop 
1 set of outcome measures for both GCA and TA (without any modifications for GCA and 
TA); and 22% said that the 2 diseases were unsuitable for common outcome measures.
Differences between experienced and inexperienced investigators. There were many 
similarities among both the experienced and inexperienced groups. The differences for GCA 
were that interleukin 6 (IL-6) levels, dizziness, cranial neuropathy, HAQ, and a rise in 
creatinine were items considered important only according to the inexperienced participants, 
whereas fever, hemoglobin/hematocrit, cardiovascular (CV) items including new bruits, loss 
of pulse or inequality, carotidynia, stroke, hemiparesis, and Vasculitis Damage Index were 
items accepted only by the experienced participants. Inexperienced participants accepted 
only TA, IL-6, weight loss, European quality of life index, HAQ, and rise in creatinine. 
Experienced investigators accepted only arthralgia, myalgia, blurred vision, syncope, 
worsening in headache, and hemiparesis.
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DISCUSSION
The results of this Delphi exercise may help future studies in outlining the range of 
candidate elements and subdomains to consider when advancing the development of 
outcome measures of disease activity in LVV in clinical trials. The items that were endorsed 
include manifestations from the CV, renal, gastrointestinal (GI), nervous, ocular, and 
musculoskeletal systems. The exclusion of the genitourinary and respiratory systems is 
consistent with previous publications in which these systems are not sites of LVV-related 
disease activity10. Not all the assessments of specific systems had the same “weight of 
importance” according to the experts. There was only 1 item in the GI (abdominal vasculitic 
pain) and renal (rise in blood pressure) sections that was accepted, whereas CV and nervous 
systems had markedly more items retained, as expected.
The results of this Delphi study demonstrate that most experts in the management of LVV 
agree that a large number of items for disease assessment in LVV were suitable for use in 
both GCA and TA, and that development of a common approach for disease assessment in 
both diseases would be appropriate. However, a set of additional disease-specific 
instruments for each disease was also recommended, with the potential to create 1 disease 
activity assessment tool for LVV, with minor modifications or supplemental measures for 
each type of LVV.
Our study has several strengths, including the wide variation of the experts regarding 
specialty and geographic site because physicians from 8 specialties and 23 countries on 4 
continents contributed. Large cohorts of patients with LVV have demonstrated that there are 
variations among different ethnicities in terms of frequencies of disease characteristics for 
LVV. Therefore, the efforts to include a broad range of experts enhances the generalizability
and reliability of these findings. However, about 90% of participants were from North
America or Europe, providing a somewhat unbalanced international representation. This
imbalance is also seen for the specialties, despite efforts to distribute the Delphi study to
multiple specialties. Additionally, the vast majority of the participants were rheumatologists.
Therefore, the results mostly reflect the perspectives of rheumatologists, indicative of how
the care of patients with LVV is distributed across different specialties. Further, only some
elements were evaluated by some specialists to ensure expertise was matched with a
corresponding clinical aspect of disease. Another strength of our study was inclusion of an
extensive list of different manifestations in the first round to allow for the wide group of
experts to consider all reasonable options for disease assessment.
There are also potential limitations of our study to consider, including the definition of an 
expert in LVV being defined as having seen at least 10 patients with GCA or TA in their 
career. This number may be considered too low, especially compared to more prevalent 
diseases. However, because LVV are rare diseases, drawing the threshold for “expert” from a 
higher number would significantly reduce the number of investigators able to participate; 
notably, all participants had participated in prior activities within the vasculitis research 
community. In addition, the exclusion of some participants from the analysis is not a 
common approach for Delphi exercises; however, because a Delphi should only be 
performed by experts in the area, we took this additional step. Because of the 
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epidemiological differences in LVV, an expert in GCA may not necessarily be experienced 
in TA and vice versa. Therefore, we limited the analysis to participants who were 
experienced in that area only, to increase the credibility of the results. This approach was 
planned as part of the analysis plan prior to the first round of the Delphi being initiated. 
Another limitation is the lack of a subset definition for “isolated aortitis”11; disease activity 
in this group of patients might require additional approaches to activity assessment.
Our study identified a set of important items to measure in a clinical trial in LVV, but all 
items are not required to be included in an activity index. There are many items and overlap 
among some proposed items; a data-driven statistical approach to item reduction will be 
necessary.
This Delphi exercise was an important step in achieving expert consensus opinion on items 
necessary to identify disease activity in LVV and these results will guide future work in 
outcome measure development in LVV. Further studies are planned to determine a core set 
of activity domains for use in clinical trials of GCA and TA.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1.
Candidate outcome measures elements commonly accepted for both giant cell arteritis and Takayasu arteritis.
Category/Organ System Specific Candidate Element
Constitutional Fever > 38°C
Fatigue
Laboratory abnormalities Erythrocyte sedimentation rate
C-reactive protein
Hemoglobin/hematocrit
Vascular items New bruit(s)
New loss of pulse(s)
New diminished pulse(s)
Asymmetric blood pressure measurement
Pulse inequality
Extremity claudication
Gastrointestinal Abdominal pain (vasculitic)
Musculoskeletal Arthralgia
Myalgia
Patient-reported outcomes A general health-related outcome measure
SF-36 (all components)
Patient pain assessment
Patient’s global assessment
Fatigue measurement instrument
Imaging* CT angiography, PET-CT, MR angiography,
ultrasound
Cardiovascular Carotidynia
Extremity hypoperfusion/threatened limb
Chest pain: pericardial or angina
New hypertension
Other symptom attributed to vascular insufficiency
Renal Rise in blood pressure (systolic/diastolic)
Ocular Temporary vision loss (amaurosis fugax)
Blurred vision
Retinal vasculitis (thrombosis or aneurysm)
New permanent visual loss
Neurological Transient ischemic episodes
Syncope
Stroke
New/worsened headache
Hemiparesis, paraparesis
Physician-based assessments Physician’s global assessment
Relapse (general definition)
Vasculitis Damage Index
J Rheumatol. Author manuscript; available in PMC 2019 August 12.
Aydin et al. Page 9
Category/Organ System Specific Candidate Element
Increase in glucocorticoid dose
New/increased immunosuppressive medication
DEI.Tak
*
Different abnormalities on different imaging modalities were voted on separately. SF-36: Medical Outcomes Study Short Form-36; CT: 
computerized tomography; PET: positron emission tomography; MR: magnetic resonance; DEI.Tak: disease extent index for Takayasu arteritis.
Aydin et al. Page 10
Table 2.
Imaging findings by different modalities accepted as potential measures of disease activity for both giant cell 
arteritis and Takayasu arteritis.
Modality Findings
CT angiography Arterial stenosis
Aneurysm
Arterial wall thickening
Arterial wall enhancement
PET-CT Total uptake values
Individual artery update values
Relative uptake compared to liver
MR angiography Arterial stenosis
Aneurysm
Arterial wall thickening
Arterial wall enhancement
Ultrasound Arterial stenosis
Aneurysm
Arterial wall thickening
CT: computerized tomography; PET: positron emission tomography; MR: magnetic resonance.
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Table 3.
Items accepted for only 1 form of large-vessel vasculitis.
Variables Details
Giant cell arteritis
Constitutional Weight loss
Cutaneous Scalp necrosis
Scalp tenderness
Musculoskeletal Morning stiffness
Ocular Scotoma
Diplopia
Imaging Vascular ultrasound: halo sign*
Takayasu arteritis
Imaging Conventional catheter-based angiography
Conventional catheter: stenosis
Conventional catheter: aneurysm
Nervous system Dizziness
*Vascular halo sign was only circulated in the first round because of a technical error. It was accepted for giant cell arteritis, but not for Takayasu 
arteritis.
